Abstracts

FROM NAFLD TO MAFLD: IMPLICATIONS OF CHANGE IN TERMINOLOGY IN PWH

Metabolic associated fatty liver disease (MAFLD) has been recently proposed as a new concept to describe nonalcoholic fatty liver disease (NAFLD), based on positive diagnostic criteria rather than exclusionary ones. The ongoing debate regarding NAFLD/MAFLD construct has not yet reached HIV arena. Our objective was to characterize MAFLD in comparison to NAFLD and to determine…

THE PATHWAY OF NAFLD VS MAFLD TOWARD SIGNIFICANT FIBROSIS

The ongoing debate regarding nonalcoholic fatty liver disease (NAFLD)/metabolic-associated fatty liver disease (MAFLD) should consider risk of progression of fatty liver disease (FLD). We aimed to describe transition of NAFLD and MAFLD states towards significant fibrosis in people with HIV (PWH). This was a longitudinal study of two prospective cohorts of PWH on stable antiretroviral…

HIV DRUG RESISTANCE IN WOMEN RANDOMIZED TO DTG VS EFV OR TDF VS TAF IN PREGNANCY

Virologic failure (VF) and HIV drug resistance (HIVDR) in pregnant and postpartum women with dolutegravir (DTG)-containing antiretroviral treatment (ART) are not well described. We compared VF and HIVDR by study arm in IMPAACT 2010, a randomized trial of 3 ART regimens started in pregnancy (DTG+emtricitabine (FTC)/tenofovir alafenamide (TAF); DTG+FTC/tenofovir disoproxil fumarate (TDF); or efavirenz (EFV)/FTC/TDF.…